Video

Frederick Munschauer: Treatment of Progressive Multiple Sclerosis Remains a Daunting Task

Author(s):

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help them.

There has been work done in this area of research and medications, including Ocrelizumab working through the approval process but Frederick Munschauer, MD, from EMD Serono said the process of developing more treatment options is still ongoing. Munschauer discussed the topic during an interview with MD Magazine during the annual meeting of the Consortium of Multiple Sclerosis Centers in National Harbor Maryland.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.